Bay Street News, January 3rd, 2019

Appointment adds regulatory expertise as Translate Bio advances early and mid-stage pipeline programs LEXINGTON, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) […]

– Enrollment and dosing of patients with giant cell arteritis commenced in global Phase 2 study HAMILTON, Bermuda, Jan. 03, […]

Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid […]

— Received approval to begin multiple-ascending dose in Phase 1/2 clinical trial of MRT5005, an mRNA therapeutic for CF — […]

Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into […]

SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the […]

VANCOUVER, British Columbia, Jan. 03, 2019 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (“Amerigo” or the “Company”) (TSX: ARG) is pleased […]

TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (TSX: FFH and FFH.U) announces that it has declared […]

TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Gran Colombia Gold Corp. (TSX: GCM; OTCQX: TPRFF) announced today that its Board […]

TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Internet of Things Inc. (TSX VENTURE: ITT; OTC: INOTF; FRANKFURT: 7IT) (“ITT” or […]